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Background: Brain-derived neurotrophic factor (BDNF) protein or mRNA levels may be
involved in the pathophysiology of bipolar disorder. However, the results were inconsis-
tent. We aimed to simultaneously investigate the relationship of BDNF protein and mRNA
levels in peripheral blood of patients with bipolar mania.
Methods: Patients with bipolar mania (n ¼ 30) and healthy controls (n ¼ 30) were recruited
during our one-year study. Psychiatric diagnoses were made according to Diagnostic and
Statistical Manual of Mental Disorders, 4th Edition criteria. The scores of the Young Mania
Rating Scale (YMRS) of patients with bipolar mania were greater than 26. All participants
had peripheral blood drawn to analyze the serum BDNF protein and mRNA levels.
Results: Using t-test, patients with bipolar mania had a lower BDNF protein and mRNA
levels than did the healthy controls (p < 0.001 and 0.049, respectively), however, the sta-
tistical significances were lost after analysis of co-variance adjusted for age and body mass
index. Twenty seven out of 30 patients with bipolar mania remained in the study after the 4
weeks of mood stabilizer treatment. Patients' BDNF protein and mRNA levels did not
change significantly after 4-week treatment.
Conclusions: Our study found that serum BDNF protein and mRNA levels in patients with
bipolar mania were lower than healthy controls, but a larger sample size will be needed to
confirm this finding.hiatry, Kaohsiung Chang Gung Memorial Hospital, 123, Dapi Rd., Niaosong, Kaohsiung 833,
886 7 7326817.
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Scientific background
Brain-derived neurotrophic factor (BDNF) has been sug-
gested as a molecular candidate for developing bipolar
disorder. Blood BDNF protein levels and its relationship
with various mood states of bipolar disorder had been
extensively studied, but studies regarding BDNF mRNA
in bipolar disorder were scarce.
What this study adds to the field
We aimed to simultaneously investigate the relationship
of BDNF protein and mRNA levels in peripheral blood of
patients with bipolarmania. Further investigationwith a
larger sample size would better reveal the relationship
between BDNF protein and mRNA levels with the path-
ophysiology of bipolar mania.Several studies have adopted the brain-derived neuro-
trophic factor (BDNF) as a molecular candidate for developing
bipolar disorder [1e8]. BDNF can cross the bloodebrain barrier
in both directions [9,10]. Blood BDNF levels correlate positively
with cortical BDNF levels in mice, rats, and pigs [9,11]. These
findings suggest that BDNF measured in blood could reflect
illness activity in the brain.
Bipolar disorder is a unique psychiatric disease which
features three distinct mood states: manic, depressive, and
euthymic states. Blood BDNF protein levels and its relation-
ship with various mood states of bipolar disorder had been
extensively studied [12,13], though not all studies are consis-
tent [14]. Studies regarding BDNF mRNA in bipolar disorder
were scarce and did not separate the different mood states in
the data analysis [15,16]. Themanic state of bipolar disorder is
usuallymanaged by bothmood stabilizers and antipsychotics,
and earlier studies found an increase in BDNF levels following
the treatment for acute mania [12].
Overall, the data of BDNF protein levels in bipolar disorder
had been inconsistent, and the data of BDNF mRNA levels in
bipolar mania had been scarce, this study aimed to simulta-
neously investigate BDNF protein and mRNA levels in the
peripheral blood of patients with bipolar mania, before and
after 4-week treatment, compared to healthy subjects.Methods
Subjects
From November 2012 to July 2015, patients diagnosed with
bipolarmaniawere evaluated according to the DSM-IV criteria
using a semi-structured interview [17]. Patients with bipolar
mania who were unmedicated for a period of at least 2 weeks
and scored over 26 on the Young Mania Rating Scale (YMRS)
[18] were recruited for the study. Healthy controls were eval-
uated with the Chinese Health Questionnaire-12 [19]. No
participants had systemic diseases, such as cardiovasculardisease, liver disease, or thyroid disease. The patients were
excluded if they were heavy smokers, alcohol dependent, or
illicit substance abusers. All experiments were performed in
accordance with relevant guidelines and regulations.
Approval was obtained from the ethics committee of the
Institutional Review Board of Chang Gung Memorial Hospital.
All patients and the healthy controls had the ability to provide
written informed consent. All assessmentswere conducted by
the same senior psychiatrist. The severity of YMRS was
assessed again after a 4-week treatment.
Mood stabilizers consisting of either valproate
(600e1500mg/d) or lithium(900e1200mg/d)wereadministered
during the hospitalization. Some patients' treatment regimens
also include other psychotropic drugs, including risperidone
(1e4 mg/d), olanzapine (5e15 mg/d), lorazepam (1e3 mg/d), or
hypnotics (i.e., zolpidem, 10e20 mg/d). 15 mL of venous blood
was obtained from each participant. Another 15 mL of venous
bloodwere drawn again frompatientswith bipolarmania after
a 4-week treatment. Blood samples were collected in the
morning at 7:00 a.m. after the patients fasted for 8 h.
Serum BDNF protein levels
Serum BDNF protein levels were measured using a commer-
cially available ELISA kit of the sandwich type (BDNF Emax
Immunoassay System; Promega; USA). Each system contained
anti-BDNF mAb, Block&Sample 5X buffer, BDNF standard,
antihuman BDNF pAb, anti-IgY HRP, TMB solution, peroxidase
substrate, and protocol. All samples were assayed or dupli-
cated by the same senior technologist.
mRNA isolation and reverse transcription polymerase chain
reaction
Peripheral blood (2.5 mL) was collected using a PAXgene Blood
RNA Tube (Qiagen) and extracted using a PAXgene Blood RNA
Kit. The total RNA (1 mg) was reverse-transcribed into cDNA by
using a High Capacity cDNA Reverse Transcription Kit
(Applied Biosystems). The PCR of BDNF and b-actin gene
expression (primer pairs ordered from Promega Biosciences)
were conducted using SYBR Green (Applied Biosystems), using
5 mL of cDNA in a 20-mL final volume and 0.5 mM of each primer
(final concentration). Quantitative PCR was performed using a
7500 Fast Real-Time PCR System (Applied Biosystems) for 45
cycles at 95 C for 5 s, at a specific annealing temperature of
60 C for 5 s and 72 C for 12 s. Amplification specificity was
investigated using the melting curve following the manufac-
turer instructions. The results were analyzed using 7500 Fast
Real-Time PCR System Software v1.4.1 (Applied Biosystems).
Gene expression levels were expressed as the concentration
ratios between PCR products and b-actin in the same sample.
Data analysis
All results were expressed as mean ± standard deviation (SD).
The statistical differences of BDNF protein levels and mRNA
levels between patients with bipolar mania and healthy con-
trols were determined by t-tests and analysis of covariance
(ANCOVA) with age and body mass index (BMI) adjustment.
The statistical differences of BDNF protein levels and mRNA
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were determined by paired t-tests. Pearson correlation was
performed between BDNF protein levels, BDNF mRNA levels,
YMRS score, and illness duration. A pvalue less than0.05 was
considered to be statistically significant.Fig. 1 e Expression of BDNF protein levels in controls and
bipolar disorder. *: p < 0.05.Results
During this period, 30 patients with bipolar mania and 30
healthy controls were recruited for this study. Table 1 lists the
demographic data, and serum BDNF protein and mRNA levels
at baseline in all participants. 27 patients with bipolar mania
remained in the study after the 4-week treatment.
Using t test, patients with bipolar mania had a lower BDNF
protein level than did the healthy controls (t¼ 6.361, p < 0.001)
[Fig. 1]. However, no significant difference existed after an
ANCOVA with age and BMI adjustment (F ¼ 0.080, p ¼ 0.778).
After the 4-week treatment with mood stabilizers, the pa-
tients' BNDF protein level did not change significantly from
the baseline (t ¼ 0.753, p ¼ 0.458).
The results of a t test revealed that the patients with bi-
polar mania had lower BDNF mRNA levels than did the
healthy controls (t ¼ 2.013, p ¼ 0.049) [Fig. 2]. However, no
significant differencewas observed based on an ANCOVAwith
age and BMI adjustment (F¼ 0.021, p¼ 0.885). After the 4-week
treatment with mood stabilizers, the patients' BNDF mRNA
level appeared to increase from the baseline, but did not reach
statistical significance (t ¼ 1.578, p ¼ 0.127).
Pearson correlation revealed no significant correlations
between BDNF protein levels, BDNFmRNA levels, YMRS score,
and illness duration.Discussion
In this study, we found that BDNF mRNA levels are lower in
the patients of bipolar mania in the t test, however, no sta-
tistical significance was found after ANCOVA adjusted with
age and BMI. Most earlier studies concerning BDNFmRNA and
bipolar disorder utilized postmortem brains. BDNF mRNA
levels were lower in bipolar group as compared to the control
group [20,21]. BDNF mRNA levels were also decreased in layer
VI of inferior temporal gyrus in layer V and/or VI of superiorTable 1 e Demographic data and serum BDNF protein and mR
Diagnostic groups Age Education (years) Du
illn
Healthy controls (n ¼ 30) 30.2 ± 5.1 17.4 ± 1.7 e
Men (n ¼ 16) 30.0 ± 5.0 17.9 ± 1.8 e
Women (n ¼ 14) 30.5 ± 5.4 16.8 ± 1.3 e
Bipolar mania
(n ¼ 30)
39.3 ± 11.3 12.2 ± 1.7 1
Men (n ¼ 14) 43.0 ± 10.9 12.4 ± 0.8 1
Women (n ¼ 16) 36.1 ± 11.0 12.1 ± 2.3 9
After treatment (n ¼ 27)
Men (n ¼ 13)
Women (n ¼ 14)
BDNF ¼ brain-derived neurotrophic factor; YMRS ¼ Young Mania Ratingtemporal gyrus [16] and cornu ammonis subfield 4 [22] in bi-
polar disorder. A study focused on pediatric patients found
BDNF mRNA levels in lymphocytes were lower in bipolar
disorder patients compared to healthy controls [15]. The bi-
polar disorder patients from aforementioned studies included
patients in both manic and depressive episode. The strength
of our study is the selectivity of recruitingmanic patients only.
Our other finding is that serum BDNF protein levels are
lower in the patients of bipolar mania in the t test, however,
no statistical significance was found after ANCOVA adjusted
with age and BMI. This finding is in line with most earlier
studies. A recentmeta-analysis of six depressive, eight manic,
and nine euthymic state studies showed that BDNF levels
were decreased in patients with an acute depressive episode
and an acute manic episode, and no significant differences
were detected in BDNF levels of euthymic patients when
compared with control subjects [13]. An earlier meta-analysis
of thirteen studies found similar results [12]. However, our
earlier investigation found no significant differences in serum
BDNF protein levels between patients with bipolar mania and
healthy controls [14]. This discrepancy could be caused by the
small sample size of our previous investigation. Our finding inNA levels of patients with bipolar mania and controls.
ration of
ess (years)
BDNF protein
levels (ng/ml)
BDNF mRNA
levels
YMRS score
9.8 ± 3.1 2.2 ± 2.9
8.8 ± 3.3 1.4 ± 1.8
11.0 ± 2.4 3.0 ± 3.7
4.0 ± 10.4 4.0 ± 3.9 0.9 ± 0.8 35.3 ± 6.8
8.8 ± 7.8 4.2 ± 4.3 0.8 ± 1.0 36.2 ± 6.9
.9 ± 10.9 3.9 ± 3.6 1.0 ± 0.5 34.5 ± 6.8
5.0 ± 6.3 1.4 ± 2.0 4.7 ± 7.4
4.5 ± 7.7 1.3 ± 1.8 5.4 ± 10.1
5.4 ± 4.9 1.5 ± 2.2 4.0 ± 7.2
Scale.
Fig. 2 e Expression of BDNF mRNA levels in controls and
bipolar disorder. *: p < 0.05.
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decreased in patients in an acute manic state.
We found no significant increase of BDNF protein and
mRNA levels after four weeks of mood stabilizer treatment. A
meta-analysis of thirteen studies found an increase in BDNF
levels following the treatment for acute mania [12]. After an
average of 52 days of treatment, the initially decreased BDNF
levels of acute manic patients showed a sharp increase [23]. In
another study, after 8 weeks of treatment, pediatric bipolar
patients had significantly higher BDNF mRNA levels [15]. In
contrast, our earlier work also found no significant change in
serum BDNF protein levels after a 4-week treatment with
mood stabilizers [14]. A possible explanation could be our
shorter follow-up time, because in this study, BDNF mRNA
levels did show a trend of increase after treatment but did not
reach statistical significance. Another explanation is the
frequent co-prescription of antipsychotics for treating bipolar
mania. Different antipsychotics may have different effect on
BDNF protein and mRNA levels. In rats, haloperidol decreased
BDNF protein and mRNA levels, while olanzapine increased
BDNF protein and mRNA levels [21]. Patients treated with
antipsychotics and/or lithium had lower serum BDNF levels
while patients treated with valproate and/or antidepressants
had higher serum BDNF levels [24]. After a 16 week follow-up,
extended-release quetiapine increases BDNF levels with time
in those with a depressive episode, but decreases BDNF levels
with time in those with a manic/mixed episode [25]. The
frequent co-prescription of antipsychotics in addition tomood
stabilizer to treat acute manic patients made the change of
BDNF protein and mRNA levels after treatment difficult to
interpret.
The small sample size is one limitation of this study. The
prescription of antipsychotics in addition to mood stabilizers
also made the interpretation difficult. The shorter follow-up
period, compared to other studies, could also cause differ-
ences in the findings. A randomized controlled study with a
longer follow-up period and larger sample size could further
investigate these questions.Conclusion
Our study found that serum BDNF protein andmRNA levels in
patients with bipolar mania were lower than healthy controls,
but a larger sample size will be needed to confirm this finding.Conflicts of interest
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